These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

76 related articles for article (PubMed ID: 8879704)

  • 41. Beneficial effects of oral clodronate in the management of malignant osteolysis and hypercalcaemia.
    Aranko K; Hanhijärvi H; Humphreys M; Drake J; Lawton WA
    Bone; 1995 Feb; 16(2):275-8. PubMed ID: 7756058
    [No Abstract]   [Full Text] [Related]  

  • 42. [Evaluation of the new formulations of aspirin tablets in bioavailability].
    Bao JX; Fu YK; Xu AX; Li SN; Wu YM
    Yao Xue Xue Bao; 1982 Jul; 17(7):540-5. PubMed ID: 7180486
    [No Abstract]   [Full Text] [Related]  

  • 43. [Bioavailability in man of oral formulations of flunarizine (drops and capsules)].
    De Caro G; Maggi L
    Boll Chim Farm; 1984 Oct; 123(10):65S-70S. PubMed ID: 6529492
    [No Abstract]   [Full Text] [Related]  

  • 44. Comparative bioavailability of two acebutolol formulations.
    Verbesselt R; Tjandramaga TB; Mullie A; De Schepper PJ
    Boll Chim Farm; 1978 Feb; 117(2):102-6. PubMed ID: 743358
    [No Abstract]   [Full Text] [Related]  

  • 45. Effects of calcium and lipophilicity on transport of clodronate and its esters through Caco-2 cells.
    Raiman J; Niemi R; Vepsäläinen J; Yritys K; Järvinen T; Mönkkönen J
    Int J Pharm; 2001 Feb; 213(1-2):135-42. PubMed ID: 11165101
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Symptomatic hypocalcemia with oral clodronate.
    Johnson MJ; Fallon MT
    J Pain Symptom Manage; 1998 Feb; 15(2):140-2. PubMed ID: 9494315
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Subcutaneous clodronate.
    Walker P; Watanabe S; Lawlor P; Bruera E
    Lancet; 1996 Aug; 348(9023):345-6. PubMed ID: 8709722
    [No Abstract]   [Full Text] [Related]  

  • 48. Bioequivalence of doxycycline tablets and capsules.
    Cohen RK; Grauer F; Weisenberg E
    Isr J Med Sci; 1980 Jul; 16(7):454-6. PubMed ID: 7399882
    [No Abstract]   [Full Text] [Related]  

  • 49. [The bioavailability of tetracycline tablets manufactured by pharmaceutical factories in China (author's transl)].
    Li T; Meng JX; Liu DY; Zhu SF; Lu SZ; Gao XY; Shen LL; Yang WS
    Yao Xue Xue Bao; 1981 Nov; 16(11):842-8. PubMed ID: 7342680
    [No Abstract]   [Full Text] [Related]  

  • 50. The bioavailability of drugs.
    Mishra B; Bhattacharya SK
    Natl Med J India; 1993; 6(2):85-8. PubMed ID: 8477218
    [No Abstract]   [Full Text] [Related]  

  • 51. [Bioavailability of clofibrate. Comparative studies on Regelan and Bioscleran].
    Gugler R; Jensen CJ
    MMW Munch Med Wochenschr; 1977 Sep; 119(35):1109-10. PubMed ID: 408665
    [No Abstract]   [Full Text] [Related]  

  • 52. Generic propoxyphene: need for clinical bioavailability evaluation.
    DeSante KA; Stoll RG; Kaiser DG; DiSanto AR
    J Pharm Sci; 1977 Dec; 66(12):1713-6. PubMed ID: 579187
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Oral bioavailability of triamcinolone tablets and a triamcinolone diacetate suspension.
    Hochhaus G; Pörtner M; Barth J; Möllmann H; Rohdewald P
    Pharm Res; 1990 May; 7(5):558-60. PubMed ID: 1973290
    [No Abstract]   [Full Text] [Related]  

  • 54. Nonequivalence of phenytoin capsules and tablets.
    Raebel MA
    N Engl J Med; 1983 Oct; 309(15):925. PubMed ID: 6888489
    [No Abstract]   [Full Text] [Related]  

  • 55. [Bioavailability of 3 peroral potassium preparations].
    Jørgensen S; Backer V; Langhoff E
    Ugeskr Laeger; 1981 May; 143(19):1216-8. PubMed ID: 7029839
    [No Abstract]   [Full Text] [Related]  

  • 56. [Studies on the biological availability of vibramycin in humans].
    Zaremba M; Karpińska B; Sobaniec H; Kacprzak-Wiatr A; Grygiel J; Konopiński P; Zakrzewska I; Czeczuga-Semeniuk E; Borowski J
    Acta Pol Pharm; 1984; 41(6):695-701. PubMed ID: 6536191
    [No Abstract]   [Full Text] [Related]  

  • 57. Contributions to medicine from bioavailability studies.
    Sharoky M
    Md Med J; 1987 Jul; 36(7):585-8. PubMed ID: 2888000
    [No Abstract]   [Full Text] [Related]  

  • 58. Bioequivalency of Khellin tablets.
    Said SA
    Pharmazie; 1981 Dec; 36(12):861-2. PubMed ID: 7330089
    [No Abstract]   [Full Text] [Related]  

  • 59. [Biorhythms of bioavailability ("chronogalenics")].
    Hüttenrauch R
    Pharmazie; 1980; 35(11):709-11. PubMed ID: 7465616
    [No Abstract]   [Full Text] [Related]  

  • 60. Therapeutic risks associated with pharmaceutical alternatives.
    N Engl J Med; 1986 Sep; 315(13):834. PubMed ID: 3748098
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.